
DURECT (DRRX) Stock Forecast & Price Target
DURECT (DRRX) Analyst Ratings
Bulls say
Durect Corp's pipeline, particularly the larsucosterol product, demonstrates promising potential for clinically meaningful mortality reductions, with notable trends indicating a 41% reduction in the 30 mg dose group and a 35% reduction in the 90 mg dose group at 90 days. The company's strategic management plans to initiate a Phase 3 trial for larsucosterol upon securing funding, which highlights their commitment to advancing this key asset. Furthermore, Durect intends to explore new partnership opportunities for POSIMIR once it regains rights, indicating operational strategies that could enhance future revenue streams and bolster overall financial health.
Bears say
Durect Corp reported a net loss of $4.3 million for the third quarter of 2024, with operating expenses comprising $2.2 million in research and development and $3.2 million in general and administrative costs. The company faces significant "going concern" risks due to its cash runway, which is projected to last only through early 2025, raising concerns about its financial sustainability in the near term. Moreover, uncertainties regarding the financing of the Phase 3 trial for larsucosterol and challenges related to the study's design have further compounded the negative outlook for the company's future growth prospects.
This aggregate rating is based on analysts' research of DURECT and is not a guaranteed prediction by Public.com or investment advice.
DURECT (DRRX) Analyst Forecast & Price Prediction
Start investing in DURECT (DRRX)
Order type
Buy in
Order amount
Est. shares
0 shares